SIPONIMOD FUMARIC ACID (Mayzent®)
Clinical Indication
Secondary progressive multiple sclerosis in adults
Comments
In line with NICE TA656
Date of classification
February 2020
Red
Medicines which should be prescribed only in a specialist setting usually within a secondary or tertiary care service. NB: Some highly specialised RED medicines e.g. injectable treatments for cancer are not included on the LLR APC website list.